trial
as of 2026-07-01Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
NCTId NCT01495169
at a glance
Phase 1 · Completed
Enrollment 33 (actual)
Sponsored by Vanda Pharmaceuticals
Primary completion 2015-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
33 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-10
Primary completion
2015-02
Eligibility
ALL · 12 Years · 17 Years
Interventions & indications
Sponsors
Vanda PharmaceuticalsLead Sponsor
Sites
10 total
Costa Mesa, United StatesNorth Miami, United StatesAtlanta, United StatesCoeur d'Alene, United StatesBaltimore, United StatesSt Louis, United StatesMarlton, United StatesCincinnati, United StatesCleveland, United StatesSalt Lake City, United States
Facts & assertions
4 sourced
Enrollment
33
Phase
PHASE1
Primary Completion Date
2015-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication